{"id":4037,"date":"2026-11-02T09:00:00","date_gmt":"2026-11-02T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4037"},"modified":"2026-11-02T23:23:20","modified_gmt":"2026-11-03T03:23:20","slug":"foralumab-shows-imaging-signal-in-progressive-ms","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4037","title":{"rendered":"Foralumab Shows Imaging Signal in Progressive MS"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Tiziana Life Sciences<\/p>\n

Event Type<\/strong><\/p>\n

Phase 2a topline (INFORM-MS)<\/p>\n

Modality<\/strong><\/p>\n

Intranasal fully human anti-CD3 antibody<\/p>\n

Asset<\/strong><\/p>\n

Foralumab<\/p>\n

Target<\/strong><\/p>\n

CD3<\/p>\n

Disease Area<\/strong><\/p>\n

Non-active secondary progressive multiple sclerosis<\/p>\n

Summary<\/h4>\n

Tiziana reported November 2 topline results from randomized, double-blind, placebo-controlled Phase 2a INFORM-MS in non-active secondary progressive multiple sclerosis. The 50-\u00b5g intranasal foralumab arm showed a TSPO-PET microglial-activation difference versus placebo at 12 weeks (p=0.0168); safety\/tolerability was the other primary endpoint.<\/p>\n

Forty-eight participants completed treatment. Mean fatigue-score changes from baseline were \u22126.17 at 50 \u00b5g, \u22127.18 at 100 \u00b5g, and \u22123.12 with placebo. Reported p-values of 0.035 and 0.040 test within-arm baseline change, not a definitive between-arm fatigue benefit. EDSS did not change during the three-month treatment period.<\/p>\n

Deep Analysis<\/h4>\n

Foralumab is a fully human anti-CD3 antibody delivered intranasally. Inference 1:<\/strong> the controlled PET difference supports target-linked anti-inflammatory activity; the randomized design helps, but TSPO PET is a surrogate and clinical disability benefit is unproven. Inference 2:<\/strong> dose-specific imaging and small groups may reflect variability or a nonmonotonic pharmacology; the absence of a disclosed positive 100-\u00b5g PET comparison and limited sample support caution. Full effect sizes, multiplicity plan, genotype handling for TSPO binding, and longer randomized disability outcomes would test both interpretations.<\/p>\n

Company and Product Background<\/h4>\n

Non-active secondary progressive MS causes disability accumulation without active relapses. Intranasal foralumab is intended to modulate immune signaling through CD3 engagement; the route is being explored for effects on CNS-associated inflammation.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • New human controlled imaging data; no approval, pivotal readout, or established clinical benefit.<\/li>\n
  • The company says the study was not powered to show definitive clinical differences. A future congress presentation and FDA discussion are plans, not completed outcomes.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    A meaningful biological signal in a high-unmet-need population, with clinical translation still uncertain. The next decisive step is a prespecified, adequately powered clinical endpoint with sustained follow-up.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance: 3 of 5. Signal Direction: positive for imaging; uncertain for clinical benefit. Confidence in Facts: moderate to high (company topline release, no full paper). Confidence in Interpretation: low to moderate. Missing: full dataset, between-arm fatigue test, long-term outcomes.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Tiziana reported November 2 topline results from randomized, double-blind, placebo-controlled Phase 2a INFORM-MS in non-active secondary progressive multiple sclerosis. The 50-\u00b5g intranasal foralumab arm showed a TSPO-PET microglial-activation difference versus placebo at 12 weeks…<\/p>\n","protected":false},"author":1,"featured_media":4039,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[1332,1333,551,1334,1331],"class_list":["post-4037","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-foralumab","tag-intranasal-anti-cd3","tag-multiple-sclerosis","tag-phase-2a","tag-tiziana-life-sciences"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4037","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4037"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4037\/revisions"}],"predecessor-version":[{"id":4045,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4037\/revisions\/4045"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4039"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4037"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4037"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4037"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}